See every side of every news story

Published 3 years ago • loading... • Updated 3 years ago

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Summary by Ground News

The provision is known as skinny labeling, which refers to a move by a company that seeks regulatory approval to market a generic or biosimilar medicine. By doing so, the company seeks to avoid lawsuits in which the brand-name manufacturer could claim patent infringement. Medicare saved $1.5 billion from 2015 to 2020, or nearly 5% of the $30.2 billion spent by the health care program.

1 Articles

1 Articles

All

Left

Center

1

Right

'Skinny labels' on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Skinny labeling on biosimilar drugs saved Medicare $1.5 billion between 2015 and 2020 on just five medicines during that period.

3 years ago·Boston, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center1Last Updated3 years agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

STAT broke the news in Boston, United States 3 years ago on Monday, November 28, 2022.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics